

## Special Issue

# Pharmacological Advances for Treatment in Hypertension 2.0

### Message from the Guest Editor

Noncommunicable diseases, especially cardiovascular diseases are the main leading cause of morbidity and mortality worldwide. Hypertension is the main aggravating risk factor and can negatively impact the incidence, severity, and clinical course of several types of cardiovascular disease, directly contributing to a complex set of pathological interactions. In this Special Issue, we would like to invite investigators to submit preclinical or clinical studies focusing on the pharmacological advances for the treatment of hypertension. Potential topics include, but are not limited to:

- Animal models of cardiovascular disease associated with hypertension;
- Isolation and characterization of natural products with antihypertensive effects;
- New synthetic drugs useful in the treatment of hypertension;
- Preclinical and clinical trials of synthetic drugs and plant-derived medicines;
- Systematic or narrative reviews of synthetic drugs and natural products with antihypertensive properties;
- Synergistic effects of synthetic drugs and natural products on hypertension treatment.

### Guest Editor

Prof. Dr. Arquimedes Gasparotto Junior

Laboratory of Cardiovascular Pharmacology (LaFaC), Federal University of Grande Dourados (UFGD), Dourados, Brazil

### Deadline for manuscript submissions

closed (31 July 2025)



## Pharmaceuticals

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.8  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/si/180768](https://mdpi.com/si/180768)

*Pharmaceuticals*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[pharmaceuticals@mdpi.com](mailto:pharmaceuticals@mdpi.com)

[mdpi.com/journal/  
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





# Pharmaceuticals

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.8  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/journal/  
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



## About the Journal

### Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

---

### Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)